Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Hikma Pharmaceuticals PLC logo
HIK.L
Hikma Pharmaceuticals PLC
13:26:58
1472 £
0.0000 (%0.00)
Previous Close: 1451
Day Low₺1420
Day High₺1477
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

HIK.L: Hikma Pharmaceuticals PLC Financials

Hikma Pharmaceuticals PLC Income Statement

Total revenue
Net income
Gross margin TTM
40.04%
Operating margin TTM
18.63%
Net profit margin TTM
12%
Return on investment TTM
15.82%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue3,419,263,0403,127,000,0002,875,000,0002,517,000,000
Operating income637,091,709612,000,000367,000,000591,000,000
Net income410,434,081359,000,000190,000,000188,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue3,419,263,0403,127,000,0002,875,000,0002,517,000,000
Cost of revenue2,050,128,4511,712,000,0001,468,000,0001,252,000,000
Gross profit1,369,134,5871,415,000,0001,407,000,0001,265,000,000
Research and development expenses154,168,025141,000,000149,000,000144,000,000
General and administrative expenses0568,000,000638,000,000509,000,000
Selling and marketing expenses00-6,000,0000
Selling, general and administrative expenses577,874,852568,000,000632,000,000509,000,000
Other expenses094,000,000259,000,0000
Operating expenses732,042,877803,000,0001,040,000,000976,000,000
Cost and expenses2,782,171,3282,515,000,0002,508,000,0002,228,000,000
Net interest income-96,993,129-67,000,000-80,000,000-67,000,000
Interest income11,230,7828,000,0007,000,00056,000,000
Interest expense108,223,91275,000,00090,000,00077,000,000
Depreciation and amortization216,447,824179,000,000172,000,000193,000,000
EBITDA853,539,534787,000,000791,000,000485,000,000
EBIT637,091,709608,000,000619,000,000292,000,000
Non-operating income (excl. interest)26,000,0004,000,000-252,000,000-10,000,000
Operating income637,091,709612,000,000367,000,000591,000,000
Total other income/expenses (net)-107,202,932-157,000,000-86,000,000-49,000,000
Income before tax529,888,777455,000,000281,000,000233,000,000
Income tax expense114,349,79393,000,00089,000,00042,000,000
Net income from continuing operations415,538,983362,000,000192,000,000191,000,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income410,434,081359,000,000190,000,000188,000,000
Net income deductions0000
Bottom line net income410,434,081359,000,000190,000,000188,000,000
EPS220.850.84
Diluted EPS220.850.84
Weighted average shares outstanding220,587,683222,981,366222,368,714223,728,472
Weighted average diluted shares outstanding222,684,171223,493,321222,368,714225,000,000

Hikma Pharmaceuticals PLC Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
1,490,542,804%
Total debt / assets MRQ
—
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets5,673,065,9375,133,000,0004,680,000,0004,471,000,000
Total liabilities3,066,116,5742,812,000,0002,471,000,0002,323,000,000
Total equity2,593,944,6262,310,000,0002,198,000,0002,135,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents328,119,489188,000,000205,000,000270,000,000
Short-term investments26,009,47125,000,00024,000,00022,000,000
Cash and short-term investments354,128,961213,000,000229,000,000292,000,000
Net receivables1,079,393,077905,000,000789,000,000777,000,000
Accounts receivable1,061,386,520896,000,000789,000,000777,000,000
Other receivables18,006,5579,000,00000
Inventory1,106,402,913986,000,000891,000,000776,000,000
Prepaid expenses87,031,69373,000,00072,000,00074,000,000
Other current assets17,006,19586,000,000119,000,00080,000,000
Total current assets2,643,962,8402,263,000,0002,100,000,0001,999,000,000
Property, plant and equipment (net)1,448,527,5031,326,000,0001,141,000,0001,081,000,000
Goodwill393,143,168382,000,000388,000,000389,000,000
Intangible assets777,283,059774,000,000712,000,000735,000,000
Goodwill and intangible assets1,170,426,2291,156,000,0001,100,000,0001,124,000,000
Long-term investments11,004,00662,000,00065,000,00052,000,000
Tax assets307,111,839293,000,000226,000,000192,000,000
Other non-current assets92,033,51633,000,000274,000,000-192,000,000
Total non-current assets3,029,103,0952,870,000,0002,580,000,0002,257,000,000
Other assets000215,000,000
Total assets5,673,065,9375,133,000,0004,680,000,0004,471,000,000
Total payables789,287,430462,000,000309,000,000291,000,000
Accounts payable715,260,472358,000,000309,000,000291,000,000
Other payables74,026,957104,000,00000
Accrued expenses0439,000,000388,000,000272,000,000
Short-term debt114,041,529642,000,000150,000,000139,000,000
Capital lease obligations (current)8,000,00011,000,00011,000,0009,000,000
Tax payables078,000,00074,000,00073,000,000
Deferred revenue000-148,000,000
Other current liabilities550,200,365424,000,000481,000,000366,000,000
Total current liabilities1,453,529,3251,978,000,0001,339,000,0001,077,000,000
Long-term debt1,490,542,804607,000,000975,000,0001,074,000,000
Capital lease obligations (non-current)45,016,39246,000,00055,000,00061,000,000
Deferred revenue (non-current)0001,055,000,000
Deferred tax liabilities (non-current)16,005,82818,000,00025,000,00019,000,000
Other non-current liabilities61,022,223181,000,000102,000,000-61,000,000
Total non-current liabilities1,612,587,248834,000,0001,132,000,0001,074,000,000
Other liabilities000172,000,000
Capital lease obligations53,016,39257,000,00066,000,00070,000,000
Total liabilities3,066,116,5742,812,000,0002,471,000,0002,323,000,000
Treasury stock0000
Preferred stock0000
Common stock40,014,57140,000,00040,000,00040,000,000
Retained earnings2,556,931,1472,362,000,0002,158,000,0002,092,000,000
Additional paid-in capital282,102,731282,000,000282,000,000282,000,000
Accumulated other comprehensive income/loss-285,103,82300-279,000,000
Other stockholders' equity0-374,000,000-282,000,000-558,000,000
Total stockholders' equity2,593,944,6262,310,000,0002,198,000,0002,135,000,000
Total equity2,606,949,3622,321,000,0002,209,000,0002,148,000,000
Minority interest13,004,73511,000,00011,000,00013,000,000
Total liabilities and total equity5,673,065,9375,133,000,0004,680,000,0004,471,000,000
Total investments37,013,47787,000,00089,000,00074,000,000
Total debt1,649,600,7261,306,000,0001,191,000,0001,283,000,000
Net debt1,321,481,2371,118,000,000986,000,0001,013,000,000

Hikma Pharmaceuticals PLC Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations366,531,928564,000,000608,000,000530,000,000
Cash from investing-402,266,239-381,000,000-333,000,000-607,000,000
Cash from financing59,216,857-188,000,000-337,000,000-58,000,000
Net change in cash126,138,077-17,000,000-65,000,000-156,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income410,434,081359,000,000190,000,000188,000,000
Depreciation and amortization238,000,000197,000,000190,000,000182,000,000
Deferred income tax00076,000,000
Stock-based compensation23,000,00027,000,00025,000,00022,000,000
Change in working capital-255,245,074-213,000,000-8,000,000-98,000,000
Accounts receivable-99,035,089-144,000,000-24,000,0004,000,000
Inventory-87,804,305-112,000,000-115,000,000-102,000,000
Accounts payable38,797,2500049,000,000
Other working capital-108,223,91243,000,000131,000,000-49,000,000
Other non-cash items-49,657,079194,000,000211,000,000160,000,000
Net cash from operating activities366,531,928564,000,000608,000,000530,000,000
Investments in property, plant and equipment-323,650,755-165,000,000-169,000,000-138,000,000
Acquisitions (net)-76,573,521-150,000,000-105,000,000-380,000,000
Purchases of investments-3,062,9400-27,000,000-15,000,000
Sales/maturities of investments001,000,000395,000,000
Other investing activities1,020,977-66,000,000-33,000,000-469,000,000
Net cash from investing activities-402,266,239-381,000,000-333,000,000-607,000,000
Net debt issuance307,315,071124,000,000-73,000,000430,000,000
Long-term net debt issuance315,482,913148,000,000-63,000,000430,000,000
Short-term net debt issuance-8,167,842-24,000,000-10,000,0000
Net stock issuance-36,755,290-38,000,0000-300,000,000
Net common stock issuance-36,755,290-38,000,0000-300,000,000
Common stock issuance0-38,000,00000
Common stock repurchased-36,755,29000-300,000,000
Net preferred stock issuance0000
Net dividends paid-188,881,356-175,000,000-137,000,000-125,000,000
Common dividends paid-188,881,356-175,000,000-137,000,000-125,000,000
Preferred dividends paid0000
Other financing activities-22,461,568-99,000,000-127,000,000-63,000,000
Net cash from financing activities59,216,857-188,000,000-337,000,000-58,000,000
Effect of FX changes on cash102,655,530-12,000,000-3,000,000-21,000,000
Net change in cash126,138,077-17,000,000-65,000,000-156,000,000
Cash at end of period328,119,489188,000,000205,000,000270,000,000
Cash at beginning of period201,981,411205,000,000270,000,000426,000,000
Operating cash flow366,531,928564,000,000608,000,000530,000,000
Capital expenditure-201,133,119-165,000,000-169,000,000-138,000,000
Free cash flow165,398,809399,000,000439,000,000392,000,000
Income taxes paid0000
Interest paid084,000,00000